RxDoctor Payments Data

Scott Buchowski, MD

Internal Medicine · Grand Rapids, MINPI 1790170629

Payments from drug & device makers

$17,408in general payments, 2019–2025

Across 171 payments — averaging $101.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$14K
  • AstraZeneca$793
  • Otsuka America Pharmaceutical, Inc.$499
  • Mallinckrodt Hospital Products Inc.$268
  • Akebia Therapeutics Inc$170
  • Calliditas Therapeutics US Inc.$158
  • plus $1K from 19 others

What the payments were for

  • Consulting fees$1,3007%
  • Speaking & faculty fees$10,92063%
  • Travel & lodging$9736%
  • Food & beverage$3,72121%
  • Education$4933%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,408 in reported general payments places this provider in the 95th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$157,179
Medicare patients
394
Services billed
1,071

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol92$81,075
VelphoroSucroferric Oxyhydroxide19$43,589
JardianceEmpagliflozin35$32,329
AuryxiaFerric Citrate19$25,172
Sevelamer Carbonate90$11,803
LokelmaSodium Zirconium Cyclosilicate20$11,454
KerendiaFinerenone12$7,459
Potassium Citrate ErPotassium Citrate28$4,724
Calcitriol205$3,612
Torsemide107$3,143
Calcium Acetate15$2,046
Losartan Potassium110$1,812
Potassium Chloride43$1,375
Hydralazine Hcl56$1,319
Lisinopril116$1,291

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$793$92,529112 claims
Fresenius USA Marketing, Inc.Velphoro$46$43,58919 claims
Boehringer IngelheimJardiance$149$32,32935 claims
Akebia Therapeutics IncAuryxia$170$25,17219 claims
BayerKerendia$92$7,45912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Grand Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →